Bruce Berkowitz, MD
Pulmonary Disease · Delray Beach, FLNPI 1275634982
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.1% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $239 and has fallen 92.7% since, to $17 in 2025. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 27 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$89
- Exact Sciences$74
- Lilly USA, LLC$59
- Mylan Specialty L.p.$55
- Lundbeck LLC$55
- Amgen$47
- plus $179 from 8 others
What the payments were for
- Food & beverage$51492%
- Education$448%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $89 |
| Exact Sciences | 3 | $74 |
| Lilly USA, LLC | 3 | $59 |
| Mylan Specialty L.p. | 2 | $55 |
| Lundbeck LLC | 2 | $55 |
| Amgen | 3 | $47 |
| Insmed, Inc. | 2 | $35 |
| Baxter Healthcare | 2 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Novo Nordisk | 1 | $21 |
| Inogen, Inc. | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Boehringer Ingelheim | 1 | $15 |
| AstraZeneca | 1 | $12 |
How this compares
$558 in reported general payments places this provider in the 25th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $94,474 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $19,853 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $14,237 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 56 | $1,782 |
| Ipratropium Bromide | 52 | $1,416 |
| Prednisone | 18 | $80 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Delray Beach
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.